Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Source filing unavailable
| Metric | Q4 2021 | Q4 2020 | Q4 2019 |
|---|---|---|---|
| Revenue | $7.58M | $8.75M | $12.09M |
| Net Income | -$57.65M | -$34.20M | -$14.60M |
| EPS Diluted | -$0.78 | -$0.52 | -$6.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
